Med schools failing on conflicts?

A new report from the linkurl:American Medical Student Association;http://www.amsa.org/ (AMSA) paints a gloomy picture of how US medical schools are failing to craft policies that keep the pharmaceutical industry at arm's length. The AMSA's linkurl:PharmFree Scorecard 2008,;http://www.amsascorecard.org/ released yesterday (June 3), surveyed 150 medical school's across the country, asking about the institutions' policies to limit linkurl:conflicts of interest;http://www.the-scientist.com/blog/di

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
A new report from the linkurl:American Medical Student Association;http://www.amsa.org/ (AMSA) paints a gloomy picture of how US medical schools are failing to craft policies that keep the pharmaceutical industry at arm's length. The AMSA's linkurl:PharmFree Scorecard 2008,;http://www.amsascorecard.org/ released yesterday (June 3), surveyed 150 medical school's across the country, asking about the institutions' policies to limit linkurl:conflicts of interest;http://www.the-scientist.com/blog/display/54300/ with pharmaceutical companies. According to the scorecard, only seven of the 150 medical schools received As, while some perennial physician training powerhouses - such as Harvard Medical School and New York University School of Medicine - received Fs. But are the nation's medical schools really failing at avoiding conflicts of interest? Perhaps not as badly as the AMSA's scorecard would have you believe. New York University, like 30 percent of the schools surveyed, simply didn't respond to the AMSA's request for policies. Harvard, on the other hand, may have gotten an F because its conflict of interest policies didn't mesh with the criteria laid out by the AMSA scorecard. Harvard's bad grade resulted from the fact that it reported to the AMSA that it had no conflict of interest policies that corresponded with the scorecard's specific criteria, according to the AMSA website. Harvard told the AMSA that a university-wide review of conflict of interest policies was underway, but the association could not ascertain that the review would specifically address the medical school and its unique potential for conflicts. The institutions topping the scorecard included the University of Pittsburg Medical Center, the University of California, San Francisco School of Medicine, and the Mount Sinai School of Medicine in New York. Though the scorecard suggests that most US medical schools are failing to prevent conflicts, the head of linkurl:The Prescription Project,;http://www.prescriptionproject.org/ which collaborated with the AMSA in producing the report, said that things can get better. "The schools that earned 'A' and 'B' scores are to be commended for setting a high bar and aggressively moving forward to ensure medical education, training and patient care is free of commercial bias," said executive director Robert Restuccia, in a Prescription Project linkurl:release.;http://www.prescriptionproject.org/newscenter/ "While we still have a long way to go, we are optimistic that the growing momentum for reform will change the landscape and there will be great improvement next year."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development